Other | Minimal Risk

Famotidine (Ausfam 20)

What to know about Famotidine — also sold as Ausfam 20, Ausfam 40: uses, side effects, interactions, and safety considerations for people taking it or caring for someone who is.

Famotidine (brand names: Ausfam 20, Ausfam 40) is classified as Minimal risk by AllMeds. It is a S2 medication under the TGA in Australia. H2 receptor antagonist with no work capacity impact.

Key Takeaways

  • TGA Schedule: S2 in Australia
  • Risk level: Minimal (0 points)
  • PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme

Scheduling and Classification

Jurisdiction Classification Status
Australia (TGA) S2 PBS listed

Risk Profile

Risk Level Minimal
Risk Points 0
CNS Depressant No
Respiratory Risk No

H2 receptor antagonist with no work capacity impact.

How Famotidine is regulated

Famotidine is overseen by medicines regulators in each country. The rules below explain how it's scheduled, what oversight applies, and what to discuss with your doctor or pharmacist before starting, changing, or stopping this medication.

Australia TGA / PBS / State Schemes

Classified as S2 under the Therapeutic Goods Administration (TGA).

Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.

Check this medication against your full medication list

Run a full risk assessment including Famotidine interactions and compliance checks.

Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.

Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.